DeCure for Vitamin K-dependent clotting factors, combined deficiency of, type 2
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for vitamin K-dependent clotting factors, combined deficiency of, type 2 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleVitamin K-dependent clotting factors, combined deficiency of, type 2 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedWarfarinApproved drug
Structures already discussed alongside vitamin k-dependent clotting factors, combined deficiency of, type 2 in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Computational design of stable mammalian serum albumins for bacterial expression — Warfarin has a real, experimentally solved structure in complex with this target (PDB 8A9Q, 2.0 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet rwfdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8A9Q · 2.0 Å · ligand Warfarin (RWF). Experimental structure, not a prediction.
What the evidence adds up to
Combined deficiency of vitamin K-dependent clotting factors type 2 (VKCFD2) is caused by point mutations in the vitamin K epoxide reductase gene (VKOR). A 2008 review describes it as a rare autosomal recessive disorder in which bleeding severity ranges from mild to severe. Therapy includes high oral doses of vitamin K for prophylaxis, usually resulting in only partial correction of factor deficiency, and episodic use of plasma infusions or prothrombin complex concentrate. The same review notes that recent molecular studies may provide potential targets for molecular therapeutics and pharmacogenetics, but no such therapy is described in the abstracts.
A 2021 study in forty healthy volunteers given menaquinone-7 (MK-7, vitamin K2) at 90 μg for 30 days found no significant changes in prothrombin time, activated partial thromboplastin time, or thrombin time. Activities of coagulation factors II, VII, IX, and X on day 30 showed no significant differences from baseline, and PIVKA-II levels were unchanged. The authors conclude that MK-7 at recommended dosage does not affect vitamin K-dependent coagulation factor activity and does not enhance prothrombin carboxylation in healthy individuals. This study does not address patients with VKCFD2.
A 2022 case report describes a 24-year-old female with heavy menstrual bleeding found to be deficient in vitamin K-dependent coagulation factors, with correction upon mixing study, diagnosed as vitamin K deficiency due to poor oral intake. Another 2022 report describes two patients with congenital combined vitamin K-dependent clotting factors deficiency, noting that world practice uses vitamin K1 (not registered in the Russian Federation) and prothrombin complex concentrate. No data on response rates, survival, or sample sizes beyond these individual cases are provided in the abstracts.
What is still missing: no controlled trials exist for VKCFD2; the only treatment data come from case reports and a review. No trial has tested vitamin K2 specifically in VKCFD2 patients. Patient stratification by genotype (VKCFD1 versus VKCFD2) is not addressed in treatment studies. Funding for a prospective trial with standardised outcome measures is absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Haemophilia · 2008 · 55 citations · open access
Familial deficiency of vitamin K‐dependent clotting factors
AbstractCombined deficiency of vitamin K-dependent clotting factors II, VII, IX and X (and proteins C, S, and Z) is usually an acquired clinical problem, often resulting from liver disease, malabsorption, or warfarin overdose. A rare inherited form of defective gamma-carboxylation resulting in early onset of bleeding was first described by McMillan and Roberts in 1966 and subsequently has been termed 'vitamin K-dependent clotting factor deficiency' (VKCFD). Biochemical and molecular studies identify two variants of this autosomal recessive disorder: VKCFD1, which is associated with point mutations in the gamma-glutamylcarboxylase gene (GGCX), and VKCFD2, which results from point mutations in the vitamin K epoxide reductase gene (VKOR). Bleeding ranges in severity from mild to severe. Therapy includes high oral doses of vitamin K for prophylaxis, usually resulting in partial correction of factor deficiency, and episodic use of plasma infusions or prothrombin complex concentrate. Recent molecular studies have the potential to further our understanding of vitamin K metabolism, gamma-carboxylation, and the functional role this post-translational modification has for other proteins. The results may also provide potential targets for molecular therapeutics and pharmacogenetics.
Vitamin K2 (Menaquinone-7) supplementation does not affect vitamin K-dependent coagulation factors activity in healthy individuals
AbstractBACKGROUND: Vitamin K has long been regarded as a procoagulant drug by physicians, and concerns have been raised with regard to its effects on hemostasis. Although many studies have shown that vitamin K supplementation is safe for thrombotic events, the effect of vitamin K supplementation on the activities of vitamin K dependent procoagulation factors in healthy individuals is not available. OBJECTIVES: This study aimed to investigate whether vitamin K2 supplementation at recommended doses affects the activity of vitamin K dependent procoagulation factors in healthy individuals without any anticoagulation treatment. DESIGN: Forty healthy volunteers between 25 and 40 years of age were recruited. Menaquinone-7 (MK-7) was administrated at 90 μg for 30 days. Prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and blood coagulation factors II, VII, IX, and X activities and Protein induced by vitamin K absence or antagonist-II (PIVKA-II) were measured on days 0 and 30 after MK-7 administration. RESULTS: PT, APTT, and TT showed no significant differences on day 30 when compared with baseline. The activities of coagulation factors II, VII, IX, and X on day 30 showed no significant differences with those at baseline. PIVKA-II levels were unchanged after 30 days of MK-7 supplementation. CONCLUSIONS: MK-7 supplementation at recommended dosage does not affect vitamin K-dependent coagulation factors' coagulation activity, and does not enhance the carboxylation of prothrombin in healthy individuals. This indicated that MK-7 administration does not alter hemostatic balance in healthy populations without anticoagulation treatment.
A Rare Case of Acquired Bleeding Disorder in a 24-Year-Old Hispanic Female
AbstractVitamin K is a fat-soluble vitamin that has a major role in coagulation pathways thus its deficiency can lead to major bleeding disorders. Vitamin K deficiency in an otherwise healthy adult is rare. Inadequate oral intake of vitamin K remains the most common cause of vitamin K deficiency. Here, we report a young female who presented for evaluation of heavy menstrual bleeding and was found to be deficient in vitamin K-dependent coagulation factors, with correction upon mixing study. She was diagnosed with vitamin K deficiency due to poor oral intake. With this case, we report a rare and avertible cause of major bleeding to raise awareness among clinicians about patients' daily nutritional requirements.
Pediatric Hematology/Oncology and Immunopathology · 2022 · 0 citations · open access
Congenital combined vitamin K-dependent clotting factors deficiency: case reports
AbstractCongenital combined vitamin K-dependent clotting factors deficiency is an extremely rare bleeding disorder, a few cases have been described worldwide. This coagulopathy requires a differential diagnosis with vitamin K deficiency bleeding of the newborn and coagulopathy, associated with different liver disease. The world practice of treating this hemorrhagic condition is the use of vitamin K 1 (not registered in the Russian Federation), as well as a prothrombin complex concentrate. This article describes the clinical manifestations, diagnosis and specific treatment in 2 patients with this bleeding disorder. The patients' parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.
Zenodo (CERN European Organization for Nuclear Research) · 2024 · 0 citations · open access
Vitamin K Deficiencies Along with VKDB as well as VKCF and Assessment of Vitamin K with the Help of Markers Namely Pivka- Ii to Diagnose Deficiency as Well as its Severity
AbstractVitamin K deficiency, a frequently overlooked condition, influences health across various physiological domains in a significant manner. Being a group of fat-soluble compounds, vitamin K plays an important role in essential processes namely blood clotting, bone metabolism as well as cardiovascular health. The absence of vitamin K in the human body can lead to spectrum of complications such as bleeding disorders, impaired bone development, and potential cardiovascular risks. Understanding the intricate interplay between vitamin K and these fundamental physiological functions is critical for especially healthcare professionals. Vitamin K deficiency in newborns contributes a distinct and critical concern within the realm of pediatric health care. Newborns with limited vitamin K reserves who do not receive timely intervention are prone to getting potentially life-threatening bleeding disorders, termed as Vitamin K deficiency bleeding (VKDB). One uncommon congenital bleeding condition that affects newborns is hereditary combined deficit of vitamin K-dependent clotting factor (VKCFD). This exercise describes vitamin K deficiency's origin, clinical signs, diagnostic techniques, and practical management tactics. This activity also highlights the importance of an interprofessional healthcare team especially in delivering comprehensive patient care.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
